Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 6/20 | 0.44 |
| ▸ | WEE1 | P30291 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.40 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | FLT4 | P35916 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15281040 | 0.87 | TNK2 (0.44) | TNK2WEE1FGFR1EGFRMAP4K3 | |
| SCHEMBL15787840 | 0.82 | TNK2 (0.43) | TNK2WEE1FGFR1EGFRMAP4K3 | |
| SCHEMBL16310846 | 0.81 | WEE1 (0.40) | TNK2WEE1FGFR1EGFRMAP4K3 | |
| SCHEMBL15036015 | 0.80 | PTK2 (0.48) | TNK2WEE1FGFR1EGFRMAP4K3 | |
| SCHEMBL14693040 | 0.79 | WEE1 (0.42) | TNK2WEE1FGFR1EGFRPTK2 | |
| SCHEMBL15041478 | 0.78 | WEE1 (0.42) | TNK2WEE1FGFR1EGFRMAP4K3 | |
| SCHEMBL13553838 | 0.78 | TNK2 (0.48) | TNK2WEE1MAP4K3MAP4K1PTK2 | |
| SCHEMBL15035118 | 0.77 | TNK2 (0.46) | TNK2WEE1MAP4K3MAP4K1PTK2 | |
| SCHEMBL15281140 | 0.75 | WEE1 (0.40) | TNK2WEE1FGFR1EGFRMAP4K3 | |
| SCHEMBL15035972 | 0.75 | TNK2 (0.45) | TNK2WEE1FGFR1MAP4K3MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | TNK2 7/4885WEE1 545/4885FGFR1 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.